NYSE - Delayed Quote USD

Abbott Laboratories (ABT)

107.59 +0.52 (+0.49%)
At close: April 23 at 4:00 PM EDT
107.50 -0.09 (-0.08%)
After hours: April 23 at 7:54 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
40,109,000.00
40,109,000.00
43,653,000.00
43,075,000.00
34,608,000.00
Cost of Revenue
17,975,000.00
17,975,000.00
19,142,000.00
18,537,000.00
15,003,000.00
Gross Profit
22,134,000.00
22,134,000.00
24,511,000.00
24,538,000.00
19,605,000.00
Operating Expense
15,656,000.00
15,656,000.00
16,149,000.00
16,113,000.00
14,248,000.00
Operating Income
6,478,000.00
6,478,000.00
8,362,000.00
8,425,000.00
5,357,000.00
Net Non Operating Interest Income Expense
-252,000.00
-252,000.00
-375,000.00
-490,000.00
-500,000.00
Other Income Expense
438,000.00
438,000.00
319,000.00
276,000.00
111,000.00
Pretax Income
6,664,000.00
6,664,000.00
8,306,000.00
8,211,000.00
4,968,000.00
Tax Provision
941,000.00
941,000.00
1,373,000.00
1,140,000.00
497,000.00
Net Income Common Stockholders
5,723,000.00
5,723,000.00
6,933,000.00
7,071,000.00
4,495,000.00
Diluted NI Available to Com Stockholders
5,723,000.00
5,723,000.00
6,933,000.00
7,071,000.00
4,495,000.00
Basic EPS
2.95
3.30
3.94
3.97
2.54
Diluted EPS
2.94
3.26
3.91
3.94
2.50
Basic Average Shares
1,741,034.50
1,734,076.36
1,753,000.00
1,775,000.00
1,771,230.27
Diluted Average Shares
1,750,670.25
1,749,000.00
1,764,000.00
1,789,000.00
1,786,000.00
Total Operating Income as Reported
6,478,000.00
6,478,000.00
8,362,000.00
8,425,000.00
5,357,000.00
Total Expenses
33,631,000.00
33,631,000.00
35,291,000.00
34,650,000.00
29,251,000.00
Net Income from Continuing & Discontinued Operation
5,723,000.00
5,723,000.00
6,933,000.00
7,071,000.00
4,495,000.00
Normalized Income
5,758,219.00
5,758,219.00
6,934,670.00
7,071,861.00
4,463,800.00
Interest Income
385,000.00
385,000.00
183,000.00
43,000.00
46,000.00
Interest Expense
637,000.00
637,000.00
558,000.00
533,000.00
546,000.00
Net Interest Income
-252,000.00
-252,000.00
-375,000.00
-490,000.00
-500,000.00
EBIT
7,301,000.00
7,301,000.00
8,864,000.00
8,744,000.00
5,514,000.00
EBITDA
10,544,000.00
10,544,000.00
12,131,000.00
12,282,000.00
8,841,000.00
Reconciled Cost of Revenue
16,698,000.00
16,698,000.00
17,888,000.00
17,046,000.00
13,808,000.00
Reconciled Depreciation
3,243,000.00
3,243,000.00
3,267,000.00
3,538,000.00
3,327,000.00
Net Income from Continuing Operation Net Minority Interest
5,723,000.00
5,723,000.00
6,933,000.00
7,071,000.00
4,471,000.00
Total Unusual Items Excluding Goodwill
-41,000.00
-41,000.00
-2,000.00
-1,000.00
8,000.00
Total Unusual Items
-41,000.00
-41,000.00
-2,000.00
-1,000.00
8,000.00
Normalized EBITDA
10,585,000.00
10,585,000.00
12,133,000.00
12,283,000.00
8,833,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-5,781.00
-5,781.00
-330.00
-139.00
800.00
12/31/2020 - 3/17/1980

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MDT Medtronic plc
81.29
+0.89%
 
INVO INVO Bioscience, Inc.
1.3000
+4.84%
 
PACB Pacific Biosciences of California, Inc.
1.4700
-5.77%
 
SYK Stryker Corporation
334.91
+2.21%
 
DXCM DexCom, Inc.
134.00
+1.89%
 
BSX Boston Scientific Corporation
68.99
+1.43%
 
EW Edwards Lifesciences Corporation
87.75
+0.91%
 
INSP Inspire Medical Systems, Inc.
233.93
+3.87%
 
ALGN Align Technology, Inc.
311.88
+3.68%
 
INMD InMode Ltd.
17.37
+1.34%